Viju Vijaysadan, MD
Internal Medicine · Kinnelon, NJNPI 1538110754
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $253,828 of the $324,948 with a category attached, or 78.1%. AstraZeneca accounts for 90.8% of it on its own, with 59 other manufacturers making up the rest. Among internal medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,440 payments — averaging $225.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$295K
- Mannkind Corporation$11K
- Intuity Medical Inc$5K
- Medtronic$3K
- Amgen$1K
- Bayer$1K
- plus $9K from 54 others
What the payments were for
- Speaking & faculty fees$253,82878%
- Travel & lodging$36,53511%
- Food & beverage$34,30311%
- Education$1830%
- Gifts$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$191,725
- AIRSUPRA$99,993
- AFREZZA$9,386
- Pogo Automatic Blood Glucose Monitoring System$4,979
- FARXIGA$3,365
- TEZSPIRE$1,900
- MINIMED 770G$1,684
- LOKELMA$1,497
- FASENRA$1,136
- BEVESPI AEROSPHERE$574
- RYBELSUS$351
- INPEN SMART INSULIN DELIVERY SYSTEM$158
- Kerendia$125
- BEXSERO$122
- TRELEGY ELLIPTA$121
- Repatha$120
- V-GO$120
- Xhance$117
- GUARDIAN SENSOR (3)$112
- Auvelity$109
How this compares
$324,948 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 140 | $167,831 |
| OzempicSemaglutide | 112 | $153,416 |
| FarxigaDapagliflozin Propanediol | 129 | $140,549 |
| KerendiaFinerenone | 88 | $90,191 |
| JardianceEmpagliflozin | 107 | $69,292 |
| XareltoRivaroxaban | 112 | $59,974 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 56 | $53,774 |
| EliquisApixaban | 148 | $52,863 |
| Xigduo XrDapaglifloz Propaned/Metformin | 41 | $45,638 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $44,258 |
| EntrestoSacubitril/Valsartan | 48 | $31,973 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 71 | $19,303 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 16 | $16,669 |
| Repatha SureclickEvolocumab | 20 | $16,642 |
| MyrbetriqMirabegron | 39 | $13,724 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $295,071 | $194,323185 claims |
| Lilly USA, LLCMounjaro | $319 | $167,831140 claims |
| Novo NordiskOzempic | $1,161 | $153,416112 claims |
| BayerKerendia | $1,182 | $90,19188 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $248 | $85,961123 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Shingrix | $867 | $67,129102 claims |
| PfizerEliquis, Abrysvo | $368 | $64,199184 claims |
| Johnson & JohnsonXarelto | $61 | $59,974112 claims |
| NovartisEntresto | $240 | $31,97348 claims |
| Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor | $261 | $20,22741 claims |
| AbbVieNamzaric, Linzess | $64 | $12,91122 claims |
| Collegium Pharmaceutical, Inc.Belbuca | $313 | $12,52714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Kinnelon
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
- Angel LazoSecaucus$195K
- Linda WaseSkillman$182K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.